Comparative Pharmacology
Head-to-head clinical analysis: BYOOVIZ versus PYZCHIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYOOVIZ versus PYZCHIVA.
BYOOVIZ vs PYZCHIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Biosimilar to infliximab; a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), neutralizing its activity and reducing inflammation.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
Intravenous infusion of 300 mg over 60 minutes on days 1, 15, and 29, then every 4 weeks thereafter.
None Documented
None Documented
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
Terminal elimination half-life approximately 21-25 days (mean 23 days), consistent with IgG1 monoclonal antibody clearance; supports monthly dosing.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Primarily eliminated via the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor